Loading...
Header Logo
Keywords
Last Name
Institution

Jessie Lai-Sim Au

TitleProf of Research
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentPharmaceutical Sciences
Address1110 N Stonewall Ave
Oklahoma City OK 73117-1200
Phone760/438-1155
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Zhao L, Au JL, Wientjes MG. Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships. Curr Cancer Drug Targets. 2017; 17(8):735-755. PMID: 28359247.
      View in: PubMed
    2. Au JL, Yeung BZ, Wientjes MG, Lu Z, Wientjes MG. Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities. Adv Drug Deliv Rev. 2016 Feb 01; 97:280-301. PMID: 26686425; PMCID: PMC4829347 [Available on 02/01/17].
    3. Yeung BZ, Lu Z, Wientjes GM, Au JL. High Sensitivity RT-qPCR Assay of Nonlabeled siRNA in Small Blood Volume for Pharmacokinetic Studies: Application to Survivin siRNA. AAPS J. 2015 Nov; 17(6):1475-82. PMID: 26286676; PMCID: PMC4627457.
    4. Wang J, Lu Z, Wang J, Cui M, Yeung BZ, Cole DJ, Wientjes MG, Au JL. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. J Control Release. 2015 Oct 28; 216:103-10. PMID: 26272765; PMCID: PMC4582943 [Available on 10/28/16].
    5. Au JL, Lu Z, Wientjes MG. Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer. AAPS J. 2015 Sep; 17(5):1065-79. PMID: 26089090; PMCID: PMC4540721.
    6. Cui M, Au JL, Wientjes MG, O'Donnell MA, Loughlin KR, Lu Z. Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts. J Urol. 2015 Jul; 194(1):230-7. PMID: 25681288; PMCID: PMC4512300.
    7. Gan Y, Lu J, Yeung BZ, Cottage CT, Wientjes MG, Au JL. Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin. AAPS J. 2015 Jan; 17(1):268-76. PMID: 25425294; PMCID: PMC4287294.
    8. Wientjes MG, Yeung BZ, Lu Z, Wientjes MG, Au JL. Predicting diffusive transport of cationic liposomes in 3-dimensional tumor spheroids. J Control Release. 2014 Oct 28; 192:10-8. PMID: 24995948; PMCID: PMC4169740.
    9. Au JL, Guo P, Gao Y, Lu Z, Wientjes MG, Tsai M, Wientjes MG. Multiscale tumor spatiokinetic model for intraperitoneal therapy. AAPS J. 2014 May; 16(3):424-39. PMID: 24570339; PMCID: PMC4012049.
    10. Wang J, Lu Z, Yeung BZ, Wientjes MG, Cole DJ, Au JL. Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors. J Control Release. 2014 Mar 28; 178:79-85. PMID: 24462901; PMCID: PMC3994124.
    11. Lu Z, Tsai M, Wang J, Cole DJ, Wientjes MG, Au JL. Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors. Curr Cancer Drug Targets. 2014; 14(1):70-8. PMID: 24200079.
      View in: PubMed
    12. Alvarez FJ, Kisseberth W, Hosoya K, Lara-Garcia A, Kosarek C, Murahari S, Au JL, Wientjes MG, Couto J, Couto G. Postoperative adjuvant combination therapy with doxorubicin and noncytotoxic suramin in dogs with appendicular osteosarcoma. J Am Anim Hosp Assoc. 2014 Jan-Feb; 50(1):12-8. PMID: 24216494.
      View in: PubMed
    13. Tsai M, Lu Z, Wientjes MG, Au JL. Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. J Control Release. 2013 Dec 28; 172(3):737-44. PMID: 24056144; PMCID: PMC3881265.
    14. Gao Y, Li M, Chen B, Shen Z, Guo P, Wientjes MG, Au JL. Predictive models of diffusive nanoparticle transport in 3-dimensional tumor cell spheroids. AAPS J. 2013 Jul; 15(3):816-31. PMID: 23605950; PMCID: PMC3691442.
    15. Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL, Sanderson RD. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 2013 May; 280(10):2294-306. PMID: 23374281; PMCID: PMC3651779.
    16. Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol. 2012 Jul; 70(1):49-56. PMID: 22729159; PMCID: PMC3466596.
    17. Wang J, Lu Z, Gao Y, Wientjes MG, Au JL. Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomedicine (Lond). 2011 Nov; 6(9):1605-20. PMID: 22077464; PMCID: PMC3655409.
    18. Li Y, Wang J, Gao Y, Zhu J, Wientjes MG, Au JL. Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability. AAPS J. 2011 Dec; 13(4):585-97. PMID: 21904966; PMCID: PMC3231863.
    19. Li Y, Wang J, Wientjes MG, Au JL. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev. 2012 Jan; 64(1):29-39. PMID: 21569804; PMCID: PMC3378679.
    20. Wong HL, Shen Z, Lu Z, Wientjes MG, Au JL. Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. Mol Pharm. 2011 Jun 06; 8(3):833-40. PMID: 21417439; PMCID: PMC3109178.
    21. Lu Z, Yeh TK, Wang J, Chen L, Lyness G, Xin Y, Wientjes MG, Bergdall V, Couto G, Alvarez-Berger F, Kosarek CE, Au JL. Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J Urol. 2011 Apr; 185(4):1478-83. PMID: 21334664; PMCID: PMC3655418.
    22. Au JL, Wientjes MG. Combination intravesical hyperthermia and chemotherapy for bladder cancer. Oncology (Williston Park). 2010 Nov 15; 24(12):1155, 1160. PMID: 21141698; PMCID: PMC3655413.
    23. Lu Z, Wang J, Wientjes MG, Au JL. Intraperitoneal therapy for peritoneal cancer. Future Oncol. 2010 Oct; 6(10):1625-41. PMID: 21062160; PMCID: PMC3076138.
    24. Hu L, Wientjes MG, Li J, Au JL. Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs. AAPS J. 2010 Dec; 12(4):586-91. PMID: 20625863; PMCID: PMC2976994.
    25. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010 Dec; 12(4):492-503. PMID: 20544328; PMCID: PMC2977003.
    26. Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J. 2010 Jun; 12(2):223-32. PMID: 20198462; PMCID: PMC2844509.
    27. Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, Wei Y, Li X, Bekaii-Saab T, Murgo AJ, Jensen RR, Grever M, Villalona-Calero MA. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1019-29. PMID: 20107799; PMCID: PMC2919610.
    28. Zhao L, Au JL, Wientjes MG. Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed). 2010 Jan 01; 2:241-9. PMID: 20036874; PMCID: PMC2885905.
    29. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 2009 Jan 06; 15(1):9-20. PMID: 19111877; PMCID: PMC2676231.
    30. Lerner SP, Au JL. Risk-adapted use of intravesical chemotherapy. BJU Int. 2008 Nov; 102(9 Pt B):1247-53. PMID: 19035889.
      View in: PubMed
    31. Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther. 2008 Dec; 327(3):673-82. PMID: 18780831; PMCID: PMC2774762.
    32. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL. Intravesical treatments of bladder cancer: review. Pharm Res. 2008 Jul; 25(7):1500-10. PMID: 18369709; PMCID: PMC2440939.
    33. Walsh CT, Wei Y, Wientjes MG, Au JL. Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance. J Transl Med. 2008 Jan 18; 6:4. PMID: 18205918; PMCID: PMC2267773.
    34. Ortiz R, Au JL, Lu Z, Gan Y, Wientjes MG. Biodegradable intraprostatic doxorubicin implants. AAPS J. 2007 Jun 29; 9(2):E241-50. PMID: 17907765; PMCID: PMC2751414.
    35. Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL. Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharm Res. 2007 Sep; 24(9):1691-701. PMID: 17447121; PMCID: PMC2774739.
    36. Lu D, Wientjes MG, Lu Z, Au JL. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther. 2007 Jul; 322(1):80-8. PMID: 17420296.
      View in: PubMed
    37. Hu L, Au JL, Wientjes MG. Computational modeling to predict effect of treatment schedule on drug delivery to prostate in humans. Clin Cancer Res. 2007 Feb 15; 13(4):1278-87. PMID: 17317840.
      View in: PubMed
    38. Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. Pharm Res. 2006 Nov; 23(11):2505-14. PMID: 16972183.
      View in: PubMed
    39. Kosarek CE, Hu X, Couto CG, Kisseberth WC, Green EM, Au JL, Wientjes MG. Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. J Vet Intern Med. 2006 Sep-Oct; 20(5):1172-7. PMID: 17063712.
      View in: PubMed
    40. Gan Y, Wientjes MG, Au JL. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006 Jun; 23(6):1324-31. PMID: 16741658.
      View in: PubMed
    41. Chen D, Song SH, Wientjes MG, Yeh TK, Zhao L, Villalona-Calero M, Otterson GA, Jensen R, Grever M, Murgo AJ, Au JL. Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. Pharm Res. 2006 Jun; 23(6):1265-74. PMID: 16715360.
      View in: PubMed
    42. Lu Z, Wientjes TS, Au JL. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors. Pharm Res. 2005 Jul; 22(7):1069-78. PMID: 16028007.
      View in: PubMed
    43. Xin Y, Lyness G, Chen D, Song S, Wientjes MG, Au JL. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. J Urol. 2005 Jul; 174(1):322-7. PMID: 15947683.
      View in: PubMed
    44. Yeh TK, Lu Z, Wientjes MG, Au JL. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res. 2005 Jun; 22(6):867-74. PMID: 15948030.
      View in: PubMed
    45. Wientjes MG, Zheng JH, Hu L, Gan Y, Au JL. Intraprostatic chemotherapy: distribution and transport mechanisms. Clin Cancer Res. 2005 Jun 01; 11(11):4204-11. PMID: 15930358.
      View in: PubMed
    46. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res. 2004 Dec 01; 10(23):7994-8004. PMID: 15585635.
      View in: PubMed
    47. Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res. 2004 Nov 15; 10(22):7677-84. PMID: 15570001.
      View in: PubMed
    48. Ogden A, Wientjes MG, Au JL. Suramin as a chemosensitizer: oral pharmacokinetics in rats. Pharm Res. 2004 Nov; 21(11):2058-63. PMID: 15587928.
      View in: PubMed
    49. Song S, Yu B, Wei Y, Wientjes MG, Au JL. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6058-65. PMID: 15447990.
      View in: PubMed
    50. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res. 2003 Sep; 20(9):1337-50. PMID: 14567626.
      View in: PubMed
    51. Villalona-Calero MA, Wientjes MG, Otterson GA, Kanter S, Young D, Murgo AJ, Fischer B, DeHoff C, Chen D, Yeh TK, Song S, Grever M, Au JL. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2003 Aug 15; 9(9):3303-11. PMID: 12960116.
      View in: PubMed
    52. Johnston JS, Johnson A, Gan Y, Wientjes MG, Au JL. Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm Res. 2003 Jul; 20(7):957-61. PMID: 12880279.
      View in: PubMed
    53. Jang SH, Wientjes MG, Au JL. Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular drug binding on intracellular paclitaxel pharmacokinetics: application of computational modeling. J Pharmacol Exp Ther. 2003 Feb; 304(2):773-80. PMID: 12538833.
      View in: PubMed
    54. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res. 2003 Feb 01; 63(3):579-85. PMID: 12566299.
      View in: PubMed
    55. Li D, Jang SH, Kim J, Wientjes MG, Au JL. Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan; 20(1):45-50. PMID: 12608535.
      View in: PubMed
    56. Chen D, Song D, Wientjes MG, Au JL. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res. 2003 Jan; 9(1):363-9. PMID: 12538489.
      View in: PubMed
    57. Gan Y, Mo Y, Johnston J, Lu J, Wientjes MG, Au JL. Telomere maintenance in telomerase-positive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase. FEBS Lett. 2002 Sep 11; 527(1-3):10-4. PMID: 12220625.
      View in: PubMed
    58. Au JL, Jang SH, Wientjes MG. Clinical aspects of drug delivery to tumors. J Control Release. 2002 Jan 17; 78(1-3):81-95. PMID: 11772451.
      View in: PubMed
    Au's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _